Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222

British Journal of Pharmacology

Volumn 173, Issue 3, 2016, Pages 588-600

  Doornbos, Maarten L J ^a   Pérez Benito, Laura ^b,c   Tresadern, Gary ^b   Mulder Krieger, Thea ^a   Biesmans, Ilse ^b   Trabanco, Andrés A ^b   Cid, Jose María ^b   Lavreysen, Hilde ^b   Ijzerman, Adriaan P ^a   Heitman, Laura H ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (CYCLOPROPYLMETHYL) 7 [(4 PHENYL 1 PIPERIDINYL)METHYL] 8 (TRIFLUOROMETHYL) 1,2,4 TRIAZOLO[4,3 A]PYRIDINE; GLUTAMIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; METABOTROPIC RECEPTOR 2; UNCLASSIFIED DRUG; 3-(CYCLOPROPYLMETHYL)-7-((4-PHENYL-1-PIPERIDINYL)METHYL)-8-(TRIFLUOROMETHYL)-1,2,4-TRIAZOLO(4,3-A)PYRIDINE; METABOTROPIC RECEPTOR; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; EC50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; ANIMAL; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOLECULAR MODEL;

ALLOSTERIC REGULATION; ANIMALS; CHO CELLS; CRICETULUS; HUMANS; MODELS, MOLECULAR; PIPERIDINES; PYRIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; TRIAZOLES;

EID: 84956726555     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13390     Document Type: Article

References (49)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al.,. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br. J. Pharmacol. 170: 1459-1581.
2. Ball M, Boyd A, Churchill G, Cuthbert M, Drew M, Fielding M, et al.,. (2012). Isoindolone formation via intramolecular Diels-Alder reaction. Org. Process Res. Dev. 16: 741-747.
3. Berger O, Edholm O, Jähnig F, (1997). Molecular dynamics simulations of a fluid bilayer of dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant temperature. Biophys. J. 72: 2002-2013.
4. Cartmell J, Adam G, Chaboz S, Henningsen R, Kemp JA, Klingelschmidt A, et al.,. (1998). Characterization of [3H]-(2S,2′R,3′R)-2-(2′,3′-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br. J. Pharmacol. 123: 497-504.
5. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22: 3099-3108.
6. Christopoulos A, Kenakin T, (2002). G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54: 323-374.
7. Cid JM, Tresadern G, Duvey G, Lütjens R, Finn T, Rocher J, et al.,. (2014). Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A novel positive allosteric modulator of the metabotropic glutamate 2 receptor. J. Med. Chem. 57: 6495-6512.
8. Cid JM, Tresadern G, Vega JA, de Lucas AI, Matesanz E, Iturrino L, et al.,. (2012). Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3 - A]pyridine (JNJ-42153605): A positive allosteric modulator of the metabotropic glutamate 2 receptor. J. Med. Chem. 55: 8770-8789.
9. Cid-Nuñez JM, Oehlrich D, Trabanco-Suárez A.A., Tresadern GJ, Vega Ramiro JA, and, MacDonald GJ, (2010). 1,2,3-Triazolo[4,3 - A]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders. WO 2010/130424 A1.
10. Conn PJ, Christopoulos A, Lindsley CW, (2009). Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8: 41-54.
11. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al.,. (2014). Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nat. Rev. Drug Discov. 13: 419-431.
12. Cordomí A, Caltabiano G, Pardo L, (2012). Membrane protein simulations using AMBER force field and Berger lipid parameters. J. Chem. Theory Comput. 8: 948-958.
13. Deupi X, Standfuss J, (2011). Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr. Opin. Struct. Biol. 21: 541-551.
14. Doré AS, Okrasa K, Patel JC, Serrano-Vega M, Bennett K, Cooke RM, et al.,. (2014). Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. Nature 511: 557-562.
15. Farinha A, Lavreysen H, Peeters L, Russo B, Masure S, Trabanco AA, et al.,. (2015). Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2. Br. J. Pharmacol. 172: 2383-2396.
16. Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, et al.,. (2011). N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link betw. J. Pharmacol. Exp. Ther. 336: 165-177.
17. Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, et al.,. (2006). Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 318: 173-185.
18. Goudet C, Kniazeff J, Hlavackova V, Malhaire F, Maurel D, Acher F, et al.,. (2005). Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators. J. Biol. Chem. 280: 24380-24385.
19. Gregory KJ, Dong EN, Meiler J, Conn PJ, (2011). Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology 60: 66-81.
20. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, et al.,. (2012). Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure - Activity relationships. Mol. Pharmacol. 82: 860-875.
21. Hemstapat K, Costa HD, Nong Y, Brady AE, Luo Q, Niswender CM, et al.,. (2007). A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 322: 254-264.
22. Hess B, Kutzner C, van der Spoel, D., Darr N, and, Lindahl, E., (2008). GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4: 435-447.
23. Hlavackova V, Goudet C, Kniazeff J, Zikova A, Maurel D, Vol C, et al.,. (2005). Evidence for a single heptahelical domain being turned on upon activation of a dimeric GPCR. EMBO J. 24: 499-509.
24. Isberg V, de Graaf C, Bortolato A, Cherezov V, Katritch V, Marshall FH, et al.,. (2015). Generic GPCR residue numbers - Aligning topology maps while minding the gaps. Trends Pharmacol. Sci. 36: 22-31.
25. Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, et al.,. (2003). Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 46: 3189-3192.
26. Keov P, Sexton PM, Christopoulos A, (2011). Allosteric modulation of G protein-coupled receptors: A pharmacological perspective. Neuropharmacology 60: 24-35.
27. Kniazeff J, Prézeau L, Rondard P, Pin J-P, Goudet C, (2011). Dimers and beyond: The functional puzzles of class C GPCRs. Pharmacol. Ther. 130: 9-25.
28. Lavreysen H, Ahnaou A, Drinkenburg W, Langlois X, Mackie C, Pype S, et al.,. (2015). Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor. Pharmacol. Res. Perspect. 3: e00096.
29. Lavreysen H, Langlois X, Ahnaou A, Drinkenburg W, te Riele P, Biesmans I, et al.,. (2013). Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J. Pharmacol. Exp. Ther. 346: 514-527.
30. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, et al.,. (2010). Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78: 1950-1958.
31. Liu W, Chun E, Thompson A a, Chun E, Chubukov P, Xu F, et al.,. (2012). Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337: 232-236.
32. Lundström L, Bissantz C, Beck J, Wettstein JG, Woltering TJ, Wichmann J, et al.,. (2011). Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br. J. Pharmacol. 164: 521-537.
33. Moustaine DE, Granier S, Doumazane E, Scholler P, Rahmeh R, Bron P, et al.,. (2012). Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc. Natl. Acad. Sci. U. S. A. 109: 16342-16347.
34. Muto T, Tsuchiya D, Morikawa K, Jingami H, (2007). Structures of the extracellular regions of the group II/III metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U. S. A. 104: 3759-3764.
35. Nicoletti F, Bockaert J, Collingridge GL, Conn PJ, Ferraguti F, Schoepp DD, et al.,. (2011). Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology 60: 1017-1041.
36. Niswender CM, Conn PJ, (2010). Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 50: 295-322.
37. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ,; NC-IUPHAR. (2014) The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-106.
38. Pin J-P, Duvoisin R, (1995). The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34: 1-26.
39. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al.,. (2011). Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477: 549-555.
40. Romano C, Yang W-L, O 'Malley KL, (1996). Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. 271: 28612-28616.
41. Rowe BA, Schaffhauser H, Morales S, Lubbers LS, Bonnefous C, Kamenecka TM, et al.,. (2008). Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site. J. Pharmacol. Exp. Ther. 326: 240-251.
42. Schaffhauser H, Richards JG, Cartmell J, Chaboz S, Kemp JA, Klingelschmidt A, et al.,. (1998). In vitro binding characteristics of a new selective group II metabotropic glutamate receptor radioligand, [3H]LY354740, in rat brain. Mol. Pharmacol. 53: 228-233.
43. Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, et al.,. (2003). Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64: 798-810.
44. Trabanco AA, Cid JM, (2013). mGluR2 positive allosteric modulators: A patent review (2009-present). Expert Opin. Ther. Pat. 23: 629-647.
45. Tresadern G, Cid JM, Macdonald GJ, Vega JA, de Lucas AI, García A, et al.,. (2010). Scaffold hopping from pyridones to imidazo[1,2 - A]pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor. Bioorg. Med. Chem. Lett. 20: 175-179.
46. Williams LT, Lefkowitz RJ, (1977). Slowly reversible binding of catecholamine to a nucleotide-sensitive state of the beta - Adrenergic receptor. J. Biol. Chem. 252: 7207-7213.
47. Woltering TJ, Wichmann J, Goetschi E, Knoflach F, Ballard TM, Huwyler J, et al.,. (2010). Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg. Med. Chem. Lett. 20: 6969-6974.
48. Wu H, Wang C, Gregory KJ, Han GW, Cho HP, Xia Y, et al.,. (2014). Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344: 58-64.
49. Xue L, Rovira X, Scholler P, Zhao H, Liu J, Pin J-P, et al.,. (2015). Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer. Nat. Chem. Biol. 11: 134-140.